Keywords: nastech, licensing, deal, worth, up, 89m, amylin

Nastech in licensing deal worth up to $89M with Amylin

Article | 03 July 2006

Print This

Nastech Pharmaceutical has signed an agreement with fellow US firm Amylin Pharmaceuticals to develop a nasal spray formulation of exenatide. ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in